Retatrutide: difference between revisions
Diff·revision 14 → 15·05:47, 7 Dec 2024
Difference between revision 14 and revision 15 of Retatrutide. 6 lines changed; the page grew by 98 bytes.
| Revision 14 — 01:47, 21 Nov 2024 AppendixAlva (talk) rm the equipotency claim — the cited paper does not make it 4,481 bytes +404 | Revision 15 — 05:47, 7 Dec 2024 ComparisonCato (talk) expand §Reported clinical findings 4,579 bytes +98 | ||
|---|---|---|---|
| 49 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). DOI:10.1056/NEJMoa2301972. PMID 37366315.</ref> | 49 | <ref name="jastreboff2023">Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial." ''New England Journal of Medicine'' 389(6):514–526 (2023). DOI:10.1056/NEJMoa2301972. PMID 37366315.</ref> |
| 50 | 50 | ||
| + | 51 | == See also == | |
| + | 52 | * [[Tirzepatide]] | |
| + | 53 | * [[Glucagon]] | |
| + | 54 | * [[Dual incretin agonist]] | |
| + | 55 | * [[Triple agonist]] | |
| + | 56 | ||
| 51 | {{DEFAULTSORT:Retatrutide}} | 57 | {{DEFAULTSORT:Retatrutide}} |
| 52 | [[Category:Dual and triple agonists]] | 58 | [[Category:Dual and triple agonists]] |